Scientists from Cornell University, led by researchers Rong Yang and Wenjing Tang, have developed a new topical gel that cures ear infections effectively with just a single application ...

Now, researchers in ACS Nano report a topical antibiotic gel that, applied once, cured middle ear infection within 24 hours in chinchillas. “I often receive emails from parents asking when our ...

Now, researchers report a topical antibiotic gel that, applied once, cured middle ear infection within 24 hours in chinchillas. Ear infections are a common and painful occurrence in infants and ...

Now, researchers in ACS Nano report a topical antibiotic gel that, applied once, cured middle ear infection within 24 hours in chinchillas. “I often receive emails from parents asking when our ...

Now, researchers in ACS Nano report a topical antibiotic gel that, applied once, cured middle ear infection within 24 hours in chinchillas. “I often receive emails from parents asking when our ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients with advanced colorectal cancer who were treated with an epidermal growth ...

A new topical gel called LUT014 successfully reduced the ... neck and upper trunk. Roughly 75% of patients on EGFR inhibitors will experience a skin toxicity or severe rash that negatively affects ...

“The ability to effectively treat it with a simple topical gel has the potential to greatly improve quality of life for patients and treatment outcomes.” Anti-EGFR therapies, such as cetuximab ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

Roughly 75% of patients on EGFR inhibitors will ... which is shut down by EGFR inhibitors. Because it is a topical, alcohol-based gel, it is not absorbed into the bloodstream and therefore does ...

approval to build upon its open-label Phase II trial of RECCE ® 327 Topical Gel (R327G) for the treatment of diabetic foot infections (DFI), enabling the enrollment of up to 20 additional patients.